Arabic Arabic English English French French German German
dark

Revolo Biotherapeutics Announces Positive Data from Additional Phase 1 Clinical Trial of ‘1104, its Peptide Drug for Allergic Disease‘1104 was safe and well-tolerated without serious adverse events

Revolo Biotherapeutics (“Revolo Bio” or the “Company”), a company developing therapies that reset the immune system to achieve superior long-term remission in patients with autoimmune (‘1805 a protein drug) and allergic disease (‘1104 a peptide drug), announced today positive data from a multiple ascending dose (MAD) Phase 1 clinical trial evaluating the safety and tolerability of ‘1104, a first-in-class peptide for the treatment of allergic disease Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Documentary Exposes the Alarming Truth — TV Puts Us In Hypnotic State and Suppresses Critical Thinking

Next Post

Standard Bariatrics® Titan SGS Stapling Technology for Sleeve Gastrectomy Receives FDA Clearance

Related Posts
Total
0
Share